Prevalence and characteristics of adults with atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation in the USA

Systemic inflammation increases the risk of cardiovascular events and is often present in patients with atherosclerotic cardiovascular disease (ASCVD), particularly in those who also have chronic kidney disease (CKD). However, the prevalence of systemic inflammation in patients with ASCVD and CKD is not well characterized. Here, we estimate the prevalence of ASCVD with CKD and systemic inflammation in the US population and describe the characteristics of people with ASCVD, CKD stages 3–4, and systemic inflammation, who are at high risk for cardiorenal events. Cross-sectional study using data from the National Health and Nutrition Examination Survey (NHANES) 2015–2020 continuous cycles. Adults aged ≥ 20 years with ASCVD who had high-sensitivity C-reactive protein (hsCRP) measurements. Prevalence and characteristics of adults with systemic inflammation in groups with ASCVD, with ASCVD and CKD, and with ASCVD and CKD stages 3–4. Systemic inflammation was defined as hsCRP levels ≥ 2 mg/L. Our study sample included 238,164,067 adults. In total, 8.5% had ASCVD, of whom 55.5% had systemic inflammation. The prevalence of systemic inflammation in individuals with ASCVD and CKD stages 3–4 (1.6% of the US population) was 59.1%, equating to 0.9% or > 2 million individuals in the general US adult population. In summary, over half of US adults with ASCVD and CKD stages 3–4 were estimated to have systemic inflammation. This group could benefit from weight loss strategies, lifestyle changes, and other approaches to improve cardiovascular outcomes. • In this cross-sectional study of 2015–20 NHANES data, 8.5% of US adults had ASCVD. • A total of 1.6% of US adults had ASCVD and CKD stages 3–4. • Of those with ASCVD and CKD stages 3–4, 59.3% had systemic inflammation. • Systemic inflammation is highly prevalent among groups with ASCVD and CKD. • This suggests that systemic inflammation should be considered for risk assessment.

Authors

Institutions

Publication Details

Journal
American Heart Journal Plus Cardiology Research and Practice
Published
2026-03-01
DOI
https://doi.org/10.1016/j.ahjo.2026.100772
Primary Topic
Adipokines, Inflammation, and Metabolic Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prevalence and characteristics of adults with atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation in the USA

Gamze Tombak, Riyanka Paul, Mads Faurby, Ann Marie Navar et al.
American Heart Journal Plus Cardiology Research and Practice
Adipokines, Inflammation, and Metabolic Diseases
article

Prevalence and characteristics of adults with atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation in the USA

Gamze Tombak, Riyanka Paul, Mads Faurby, Ann Marie Navar, Michael G. Nanna, Lance A. Sloan, Naveed Sattar, Lise Lotte N. Husemoen
article en

Abstract

Systemic inflammation increases the risk of cardiovascular events and is often present in patients with atherosclerotic cardiovascular disease (ASCVD), particularly in those who also have chronic kidney disease (CKD). However, the prevalence of systemic inflammation in patients with ASCVD and CKD is not well characterized. Here, we estimate the prevalence of ASCVD with CKD and systemic inflammation in the US population and describe the characteristics of people with ASCVD, CKD stages 3–4, and systemic inflammation, who are at high risk for cardiorenal events. Cross-sectional study using data from the National Health and Nutrition Examination Survey (NHANES) 2015–2020 continuous cycles. Adults aged ≥ 20 years with ASCVD who had high-sensitivity C-reactive protein (hsCRP) measurements. Prevalence and characteristics of adults with systemic inflammation in groups with ASCVD, with ASCVD and CKD, and with ASCVD and CKD stages 3–4. Systemic inflammation was defined as hsCRP levels ≥ 2 mg/L. Our study sample included 238,164,067 adults. In total, 8.5% had ASCVD, of whom 55.5% had systemic inflammation. The prevalence of systemic inflammation in individuals with ASCVD and CKD stages 3–4 (1.6% of the US population) was 59.1%, equating to 0.9% or > 2 million individuals in the general US adult population. In summary, over half of US adults with ASCVD and CKD stages 3–4 were estimated to have systemic inflammation. This group could benefit from weight loss strategies, lifestyle changes, and other approaches to improve cardiovascular outcomes. • In this cross-sectional study of 2015–20 NHANES data, 8.5% of US adults had ASCVD. • A total of 1.6% of US adults had ASCVD and CKD stages 3–4. • Of those with ASCVD and CKD stages 3–4, 59.3% had systemic inflammation. • Systemic inflammation is highly prevalent among groups with ASCVD and CKD. • This suggests that systemic inflammation should be considered for risk assessment.

American Heart Journal Plus Cardiology Research and Practice
Lankenau Institute for Medical Research (US), Novo Nordisk (Denmark) (DK), Yale University (US), Southwestern Medical Center (US), Novo Nordisk (United States) (US), Novo Nordisk (India) (IN), Southwestern Medical Center (US), The University of Texas Medical Branch at Galveston (US), University of Glasgow (GB), The University of Texas Southwestern Medical Center (US)
Zero hunger
Openalex Percentile: Top 9%
Adipokines, Inflammation, and Metabolic Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.